$ENTO
Entero Therapeutics Inc

2021 Q4 Form 10-K Financial Statement

#000114036122012347 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.037M $18.37M $2.696M
YoY Change 12.64% 152.34% -650.22%
% of Gross Profit
Research & Development $5.778M $16.99M $14.68M
YoY Change -60.64% 188.63% 811.8%
% of Gross Profit
Depreciation & Amortization $137.2K $15.00K $143.1K
YoY Change -4.14% -60.53% 2.24%
% of Gross Profit
Operating Expenses $8.815M $59.06M $17.40M
YoY Change -49.34% 123.42% 1439.71%
Operating Profit -$59.06M
YoY Change 123.42%
Interest Expense -$1.230K $11.24K -$1.720K
YoY Change -28.49% -99.81% -98.93%
% of Operating Profit
Other Income/Expense, Net -$4.280K $519.0K
YoY Change -108.32%
Pretax Income -$11.17M -$58.54M -$17.40M
YoY Change -35.79% 79.17% 1259.41%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.17M -$58.54M -$17.40M
YoY Change -35.79% 79.17% 1259.41%
Net Earnings / Revenue
Basic Earnings Per Share -$9.47
Diluted Earnings Per Share -$25.94M -$9.47 -$5.750M
COMMON SHARES
Basic Shares Outstanding 8.926M
Diluted Shares Outstanding 8.926M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.249M $8.249M $6.062M
YoY Change 36.07% 36.07% 3267.86%
Cash & Equivalents $8.249M $6.062M
Short-Term Investments
Other Short-Term Assets $1.176M $1.176M $1.256M
YoY Change -6.36% -6.36% 109.36%
Inventory
Prepaid Expenses $1.176M $1.256M
Receivables $0.00 $551.5K
Other Receivables
Total Short-Term Assets $9.425M $9.425M $7.870M
YoY Change 19.76% 19.76% 130.79%
LONG-TERM ASSETS
Property, Plant & Equipment $73.11K $409.3K $18.33K
YoY Change 298.88% 342.16% -88.54%
Goodwill $1.912M $2.054M
YoY Change -6.93% 8.87%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.292M $44.01K $5.036M
YoY Change -54.49% 57.63% 12489.36%
Total Long-Term Assets $2.365M $2.365M $5.054M
YoY Change -53.21% -53.21% -7.94%
TOTAL ASSETS
Total Short-Term Assets $9.425M $9.425M $7.870M
Total Long-Term Assets $2.365M $2.365M $5.054M
Total Assets $11.79M $11.79M $12.92M
YoY Change -8.77% -8.77% 45.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.708M $2.682M $1.686M
YoY Change 60.64% 72.07% -23.73%
Accrued Expenses $393.3K $497.1K $127.0K
YoY Change 209.62% 169.51% -15.33%
Deferred Revenue
YoY Change
Short-Term Debt $641.2K $641.2K $552.4K
YoY Change 16.08% 16.08% -63.66%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.30M $12.30M $15.55M
YoY Change -20.87% -20.87% 262.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.311M $7.311M $19.12K
YoY Change 38132.17% 38138.18%
Total Long-Term Liabilities $7.311M $7.311M $19.12K
YoY Change 38132.17% 38138.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.30M $12.30M $15.55M
Total Long-Term Liabilities $7.311M $7.311M $19.12K
Total Liabilities $19.61M $19.61M $15.56M
YoY Change 26.0% 26.0% 262.81%
SHAREHOLDERS EQUITY
Retained Earnings -$153.9M -$95.37M
YoY Change 61.38%
Common Stock $1.485K $312.00
YoY Change 375.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.822M -$7.822M -$2.641M
YoY Change
Total Liabilities & Shareholders Equity $11.79M $11.79M $12.92M
YoY Change -8.77% -8.77% 45.21%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$11.17M -$58.54M -$17.40M
YoY Change -35.79% 79.17% 1259.41%
Depreciation, Depletion And Amortization $137.2K $15.00K $143.1K
YoY Change -4.14% -60.53% 2.24%
Cash From Operating Activities -$5.863M -$32.29M -$5.890M
YoY Change -0.46% 187.73% 82.92%
INVESTING ACTIVITIES
Capital Expenditures $1.960K $69.49K -$1.360K
YoY Change -244.12% 1567.58%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$10.25M $91.52K
YoY Change -100.0% -11299.74%
Cash From Investing Activities $1.960K -$10.32M $90.16K
YoY Change -97.83% -11913.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $14.16M
YoY Change 1332.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.823M 44.76M 552.4K
YoY Change 1135.15% 162.6% -69.98%
NET CHANGE
Cash From Operating Activities -5.863M -32.29M -5.890M
Cash From Investing Activities 1.960K -10.32M 90.16K
Cash From Financing Activities 6.823M 44.76M 552.4K
Net Change In Cash 962.0K 2.156M -5.247M
YoY Change -118.33% -63.53% 280.25%
FREE CASH FLOW
Cash From Operating Activities -$5.863M -$32.29M -$5.890M
Capital Expenditures $1.960K $69.49K -$1.360K
Free Cash Flow -$5.865M -$32.36M -$5.889M
YoY Change -0.41% 188.25% 82.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001604191
CY2021 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1112546
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7821550
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2640693
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11789976
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12923855
CY2021Q4 us-gaap Assets Current
AssetsCurrent
9424952
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P63M
CY2021Q4 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilities
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Auditor Firm
AuditorFirmId
339
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37853
CY2021 dei Entity Registrant Name
EntityRegistrantName
FIRST WAVE BIOPHARMA, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4993860
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
777 Yamato Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 502
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
CY2021 dei City Area Code
CityAreaCode
561
CY2021 dei Local Phone Number
LocalPhoneNumber
589-7020
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
FWBI
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
67100000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16700640
CY2021 dei Auditor Name
AuditorName
Mazars USA LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021 dei Auditor Name
AuditorName
Mazars USA LLP
CY2021 dei Auditor Location
AuditorLocation
New York, NY
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8248684
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6062141
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
551489
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1176268
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1256154
CY2020Q4 us-gaap Assets Current
AssetsCurrent
7869784
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73110
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18329
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2879536
CY2021Q4 us-gaap Goodwill
Goodwill
1911705
CY2020Q4 us-gaap Goodwill
Goodwill
2054048
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
336197
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
74238
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
44012
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
27920
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2291914
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5035742
CY2021Q4 us-gaap Assets
Assets
11789976
CY2020Q4 us-gaap Assets
Assets
12923855
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3100984
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1685603
CY2021Q4 fwbi License Agreement Payable Current
LicenseAgreementPayableCurrent
0
CY2020Q4 fwbi License Agreement Payable Current
LicenseAgreementPayableCurrent
13250000
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
465361
CY2020Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
641236
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
552405
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8092807
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57417
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12300388
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15545425
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7311138
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19123
CY2021Q4 us-gaap Liabilities
Liabilities
19611526
CY2020Q4 us-gaap Liabilities
Liabilities
15564548
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14855848
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14855848
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3115030
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3115030
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1485
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
312
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
147305147
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
93837739
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153904047
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95366198
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1224135
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-111589
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-154009
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58649438
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32825475
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58537849
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-32671466
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
16994828
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5888004
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
21325527
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
13250000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18384545
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7294764
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2351988
CY2020 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2021 us-gaap Operating Expenses
OperatingExpenses
59056888
CY2020 us-gaap Operating Expenses
OperatingExpenses
26432768
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-59056888
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-26432768
CY2021 us-gaap Interest Expense
InterestExpense
11235
CY2020 us-gaap Interest Expense
InterestExpense
5840614
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
1173
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
484
CY2021 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2020 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
211430
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-609998
CY2021 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
532353
CY2020 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
0
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3252
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
519039
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6238698
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58537849
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-32671466
CY2021 fwbi Deemed Dividend On Preferred Stock
DeemedDividendOnPreferredStock
4507125
CY2020 fwbi Deemed Dividend On Preferred Stock
DeemedDividendOnPreferredStock
8155212
CY2021 fwbi Deemed Dividends On Preferred Stock Exchanges
DeemedDividendsOnPreferredStockExchanges
21008253
CY2020 fwbi Deemed Dividends On Preferred Stock Exchanges
DeemedDividendsOnPreferredStockExchanges
0
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
465361
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
905660
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-84518588
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41732338
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8925728
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8925728
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2843629
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2843629
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.47
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.47
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.68
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.68
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4617244
CY2020 fwbi Stock And Warrants Stock During Period Value Cash Conversion Of Promissory Notes Net Of Offering Costs
StockAndWarrantsStockDuringPeriodValueCashConversionOfPromissoryNotesNetOfOfferingCosts
14460155
CY2020 fwbi Adjustments To Additional Paid In Capital Warrant Issued Convertible Preferred Stock Private Placement
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedConvertiblePreferredStockPrivatePlacement
5952516
CY2020 fwbi Adjustments To Additional Paid In Capital Warrant Issued Inducement To Exchange Promissory Notes Into Convertible Preferred Stock Private Placement
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInducementToExchangePromissoryNotesIntoConvertiblePreferredStockPrivatePlacement
986526
CY2020 fwbi Adjustments To Additional Paid In Capital Conversion Of Convertible Securities
AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities
8155212
CY2020 fwbi Adjustments To Additional Paid In Capital Deemed Dividends Preferred Stock
AdjustmentsToAdditionalPaidInCapitalDeemedDividendsPreferredStock
8155212
CY2020 fwbi Adjustments To Additional Paid In Capital Deemed Dividends Exchange Of Promissory Notes To Preferred Stock
AdjustmentsToAdditionalPaidInCapitalDeemedDividendsExchangeOfPromissoryNotesToPreferredStock
1129742
CY2020 fwbi Stock Issued During Period Value Preferred Payment In Kind Shares For Accrued Dividends
StockIssuedDuringPeriodValuePreferredPaymentInKindSharesForAccruedDividends
0
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2020 fwbi Stock Issued During Period Value Settle Accounts Payable
StockIssuedDuringPeriodValueSettleAccountsPayable
131137
CY2020 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
144405
CY2020 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
988348
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1252558
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1838422
CY2020 fwbi Adjustments To Additional Paid In Capital Settlement For Services
AdjustmentsToAdditionalPaidInCapitalSettlementForServices
85770
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
549425
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-154009
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-32671466
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2640693
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-2640693
CY2021 fwbi Stock And Warrants Stock During Period Value Cash Net Of Offering Costs
StockAndWarrantsStockDuringPeriodValueCashNetOfOfferingCosts
7105168
CY2021 fwbi Stock Issued During Period Value License Acquired
StockIssuedDuringPeriodValueLicenseAcquired
2467649
CY2021 fwbi Adjustments To Additional Paid In Capital Conversion Of Convertible Securities
AdjustmentsToAdditionalPaidInCapitalConversionOfConvertibleSecurities
4507125
CY2021 fwbi Adjustments To Additional Paid In Capital Deemed Dividends Preferred Stock
AdjustmentsToAdditionalPaidInCapitalDeemedDividendsPreferredStock
4507125
CY2021 fwbi Stock Issued During Period Value Exchange Of Preferred Stock
StockIssuedDuringPeriodValueExchangeOfPreferredStock
-1430
CY2021 fwbi Adjustments To Additional Paid In Capital Warrant Issued Exchange Of Preferred Stock
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedExchangeOfPreferredStock
21009683
CY2021 fwbi Adjustments To Additional Paid In Capital Deemed Dividend Exchange Of Preferred Stock
AdjustmentsToAdditionalPaidInCapitalDeemedDividendExchangeOfPreferredStock
-21008253
CY2021 fwbi Stock Issued During Period Value Conversion Of Preferred Stock To Common Stock
StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStock
0
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2021 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
465361
CY2021 fwbi Stock Issued During Period Value Common Stock And Pre Funded Warrants Issued Upon Conversion Of Convertible Securities
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsIssuedUponConversionOfConvertibleSecurities
0
CY2021 fwbi Stock Issued During Period Value Common Stock Pre Funded Warrants And Warrants For Cash Net Of Offering Costs
StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndWarrantsForCashNetOfOfferingCosts
14156050
CY2021 fwbi Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
0
CY2021 fwbi Stock Issued During Period Value At The Market For Cash Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketForCashNetOfOfferingCosts
18506814
CY2021 fwbi Stock Issued During Period Value Intellectual Property Acquired Net
StockIssuedDuringPeriodValueIntellectualPropertyAcquiredNet
4000000
CY2021 fwbi Stock Cancelled During Period Value Acquisitions
StockCancelledDuringPeriodValueAcquisitions
0
CY2021 fwbi Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4906630
CY2021 fwbi Stock And Warrants Issued During Period Value Issued For Services
StockAndWarrantsIssuedDuringPeriodValueIssuedForServices
1326062
CY2021 fwbi Stock Issued During Period Value Settlement With Former Placement Agent
StockIssuedDuringPeriodValueSettlementWithFormerPlacementAgent
94499
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1371070
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-111589
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58537849
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-7821550
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-58537849
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-32671466
CY2021 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2351988
CY2020 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2021 us-gaap Depreciation
Depreciation
14707
CY2020 us-gaap Depreciation
Depreciation
37797
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
527548
CY2020 us-gaap Adjustment For Amortization
AdjustmentForAmortization
527548
CY2020 fwbi Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-110835
CY2021 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
16092
CY2020 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
15412
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1415381
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4855
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4855
CY2021 fwbi Fixed Asset Written Off
FixedAssetWrittenOff
0
CY2020 fwbi Fixed Asset Written Off
FixedAssetWrittenOff
10950
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-532353
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1371070
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
522133
CY2021 fwbi Common Stock Issued For Intellectual Property Acquired Net
CommonStockIssuedForIntellectualPropertyAcquiredNet
4000000
CY2020 fwbi Common Stock Issued For Intellectual Property Acquired Net
CommonStockIssuedForIntellectualPropertyAcquiredNet
0
CY2021 fwbi Restricted Stock Granted To Employeesdirectors
RestrictedStockGrantedToEmployeesdirectors
0
CY2020 fwbi Restricted Stock Granted To Employeesdirectors
RestrictedStockGrantedToEmployeesdirectors
27292
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1420561
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
166905
CY2021 fwbi Accreted Interest On Convertible Debt
AccretedInterestOnConvertibleDebt
0
CY2020 fwbi Accreted Interest On Convertible Debt
AccretedInterestOnConvertibleDebt
234074
CY2021 fwbi Accretion Of Debt Discount
AccretionOfDebtDiscount
0
CY2020 fwbi Accretion Of Debt Discount
AccretionOfDebtDiscount
4580168
CY2021 fwbi Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2020 fwbi Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
609998
CY2021 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2020 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
211430
CY2021 fwbi Beneficial Conversion Feature Promissory Notes
BeneficialConversionFeaturePromissoryNotes
0
CY2020 fwbi Beneficial Conversion Feature Promissory Notes
BeneficialConversionFeaturePromissoryNotes
798413
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-551489
CY2020 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2083270
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-79886
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
660845
CY2021 fwbi Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-257104
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-750027
CY2021 fwbi Increase Decrease In Payables Related To License Agreement
IncreaseDecreaseInPayablesRelatedToLicenseAgreement
0
CY2020 fwbi Increase Decrease In Payables Related To License Agreement
IncreaseDecreaseInPayablesRelatedToLicenseAgreement
13250000
CY2021 fwbi Increase Decrease In Other Operating Liabilities Related To Merger Consideration
IncreaseDecreaseInOtherOperatingLiabilitiesRelatedToMergerConsideration
15000000
CY2020 fwbi Increase Decrease In Other Operating Liabilities Related To Merger Consideration
IncreaseDecreaseInOtherOperatingLiabilitiesRelatedToMergerConsideration
0
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
327405
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
354784
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32288218
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11221538
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69488
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4167
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
91517
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10250000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10319488
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
87350
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
799772
CY2021 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
7105168
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
13197740
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14156050
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
988348
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4906630
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3227002
CY2021 fwbi Proceeds From Issuance Of Common Stock At Market For Cash Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAtMarketForCashNetOfOfferingCosts
18506814
CY2020 fwbi Proceeds From Issuance Of Common Stock At Market For Cash Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAtMarketForCashNetOfOfferingCosts
0
CY2021 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
CY2020 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
475000
CY2021 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
88831
CY2020 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-691741
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44763493
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17046121
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2155787
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5911933
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30756
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-25588
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6062141
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175796
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8248684
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6062141
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
105460
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2021 fwbi Noncash Or Part Noncash Deemed Dividends On Preferred Stock Issuances
NoncashOrPartNoncashDeemedDividendsOnPreferredStockIssuances
-4507125
CY2020 fwbi Noncash Or Part Noncash Deemed Dividends On Preferred Stock Issuances
NoncashOrPartNoncashDeemedDividendsOnPreferredStockIssuances
-8155212
CY2021 fwbi Noncash Or Part Noncash Deemed Dividends Preferred Stock Exchanges
NoncashOrPartNoncashDeemedDividendsPreferredStockExchanges
-21008253
CY2020 fwbi Noncash Or Part Noncash Deemed Dividends Preferred Stock Exchanges
NoncashOrPartNoncashDeemedDividendsPreferredStockExchanges
0
CY2021 fwbi Noncash Or Part Noncash Accrued Dividends On Preferred Stock
NoncashOrPartNoncashAccruedDividendsOnPreferredStock
-465361
CY2020 fwbi Noncash Or Part Noncash Accrued Dividends On Preferred Stock
NoncashOrPartNoncashAccruedDividendsOnPreferredStock
-905650
CY2021 us-gaap Stock Issued1
StockIssued1
2467649
CY2020 us-gaap Stock Issued1
StockIssued1
0
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
609998
CY2021Q3 fwbi Number Of Common Stock Shares Converted Into One New Common In Reverse Stock Split
NumberOfCommonStockSharesConvertedIntoOneNewCommonInReverseStockSplit
10
CY2021Q3 fwbi Number Of New Stock Issued For Every Ten Common Stock Shares Converted In Reverse Stock Split
NumberOfNewStockIssuedForEveryTenCommonStockSharesConvertedInReverseStockSplit
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8200000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153900000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8200000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153900000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153900000
CY2021 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-8000000.0
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying consolidated financial statements are prepared in conformity with GAAP and include certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements (including goodwill and intangible assets), and the reported amounts of revenue and expense during the reporting period, including contingencies. Accordingly, actual results may differ from those estimates</div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Concentrations of Credit Risk</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist of cash. The Company primarily maintains its cash balances with financial institutions in federally insured accounts in the U.S. The Company may from time to time have cash in banks in excess of FDIC insurance limits. At December 31, 2021 and 2020, the Company had approximately $7.5 million and $2.7 million, respectively, in one account in the U.S. in excess of these limits. The Company has not experienced any losses to date resulting from this practice. The Company mitigates its risk by maintaining the majority of its cash and equivalents with high quality financial institutions.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company also has exposure to foreign currency risk as its subsidiary in France has a functional currency in Euros.</div>
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
7500000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
2700000
CY2019Q3 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
420000
CY2021 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
50000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2400000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
8000000.0
CY2021Q4 fwbi Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
0
CY2020Q4 fwbi Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
493906
CY2021Q4 us-gaap Other Receivables
OtherReceivables
0
CY2020Q4 us-gaap Other Receivables
OtherReceivables
57583
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
551489
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2021Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
3802745
CY2020Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
3802745
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
87818
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
56732
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14708
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
38403
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
73110
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18329
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
38000
CY2020 fwbi Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
10000
CY2021Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
3800000
CY2021Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
3802745
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1450757
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
923209
CY2021Q4 fwbi Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
2351988
CY2020Q4 fwbi Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
0
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2879536
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
528000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
528000
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
2400000
CY2019Q4 us-gaap Goodwill
Goodwill
1886686
CY2020 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
167362
CY2020Q4 us-gaap Goodwill
Goodwill
2054048
CY2021 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-142343
CY2021Q4 us-gaap Goodwill
Goodwill
1911705
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2681914
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1558591
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
419070
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
127012
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3100984
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1685603
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
77989
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
57417
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
14818
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
0
CY2021Q4 fwbi Other Liabilities Related To Merger Consideration Current
OtherLiabilitiesRelatedToMergerConsiderationCurrent
8000000
CY2020Q4 fwbi Other Liabilities Related To Merger Consideration Current
OtherLiabilitiesRelatedToMergerConsiderationCurrent
0
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8092807
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
57417
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
311138
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19123
CY2021Q4 fwbi Other Liabilities Related To Merger Consideration Noncurrent
OtherLiabilitiesRelatedToMergerConsiderationNoncurrent
7000000
CY2020Q4 fwbi Other Liabilities Related To Merger Consideration Noncurrent
OtherLiabilitiesRelatedToMergerConsiderationNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7311138
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19123
CY2021Q4 fwbi Other Liabilities Related To Merger Consideration Current
OtherLiabilitiesRelatedToMergerConsiderationCurrent
8000000
CY2021Q4 fwbi Other Liabilities Related To Merger Consideration Noncurrent
OtherLiabilitiesRelatedToMergerConsiderationNoncurrent
7000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021 fwbi Authorization Period Of Reverse Stock Split
AuthorizationPeriodOfReverseStockSplit
P1Y
CY2021Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1706
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14855848
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14855848
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3115030
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3115030
CY2021 fwbi Number Of Votes Entitled For Each Share Of Common Stock
NumberOfVotesEntitledForEachShareOfCommonStock
1
CY2021Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
678000
CY2019Q4 fwbi Maximum Number Of Times Shares To Be Purchased Than Regular Purchase
MaximumNumberOfTimesSharesToBePurchasedThanRegularPurchase
3
CY2019Q4 fwbi Common Stock Maximum Closing Trading Price
CommonStockMaximumClosingTradingPrice
2.50
CY2019Q4 fwbi Common Stock Maximum Closing Trading Price
CommonStockMaximumClosingTradingPrice
2.50
CY2020Q3 fwbi Percentage Of Placement Agent Non Accountable Cash Fee Paid
PercentageOfPlacementAgentNonAccountableCashFeePaid
0.010
CY2020Q3 fwbi Additional Cash Fees Paid
AdditionalCashFeesPaid
300000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
137746
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.60
CY2020Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
22400000
CY2020Q3 fwbi Deemed Dividend On Preferred Stock
DeemedDividendOnPreferredStock
8200000
CY2020Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2000000.0
CY2020 fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
8075
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
537829
CY2019Q4 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
25.30
CY2020 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
1987968
CY2020 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
8.80
CY2020 fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
8075
CY2020 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired
41.10
CY2020 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2020 fwbi Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised
0
CY2020 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2517722
CY2020Q4 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
12.20
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2517722
CY2020Q4 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
12.20
CY2021 fwbi Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
4095602
CY2021 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
7.46
CY2021 fwbi Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
133346
CY2021 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired
33.98
CY2021 fwbi Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
952588
CY2021 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
5.32
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5527390
CY2021Q4 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
9.49
CY2021Q4 fwbi Class Of Warrant Or Right Exercisable Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightExercisableNumberOfSecuritiesCalledByWarrantsOrRights
5527390
CY2021 fwbi Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife
P3Y11M12D
CY2021Q4 fwbi Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Outstanding And Exercisable
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsOutstandingAndExercisable
9.49
CY2021 fwbi Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue
8.63
CY2020 fwbi Class Of Warrant Or Right Grants In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageGrantDateFairValue
5.90
CY2021 fwbi Class Of Warrant Or Right Fair Value Assumptions Expected Term
ClassOfWarrantOrRightFairValueAssumptionsExpectedTerm
P4Y4M17D
CY2020 fwbi Class Of Warrant Or Right Fair Value Assumptions Expected Term
ClassOfWarrantOrRightFairValueAssumptionsExpectedTerm
P5Y
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.05
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.90
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2000000.0
CY2021Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
3472
CY2021Q4 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P2Y
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
261000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
205000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M1D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0687
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0600
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
81254
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
83691
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
86202
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
88788
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
60593
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
400528
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11401
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
389127
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
31600000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26100000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31600000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26100000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5600000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9700000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
30576000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
24269000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
112000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1408000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
30000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
76000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
138000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
0
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
791000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
639000
CY2021Q4 fwbi Deferred Tax Assets Tax Deferred Expense Amortization
DeferredTaxAssetsTaxDeferredExpenseAmortization
0
CY2020Q4 fwbi Deferred Tax Assets Tax Deferred Expense Amortization
DeferredTaxAssetsTaxDeferredExpenseAmortization
-319000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31647000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26073000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.042
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.140
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.103
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.120
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.095
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.230
CY2021 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.047
CY2020 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.50
CY2021 fwbi Ownership Change Testing Period
OwnershipChangeTestingPeriod
P3Y
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
27100000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
23000000.0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
107000
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
92000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
6969988

Files In Submission

Name View Source Status
0001140361-22-012347-index-headers.html Edgar Link pending
0001140361-22-012347-index.html Edgar Link pending
0001140361-22-012347.txt Edgar Link pending
0001140361-22-012347-xbrl.zip Edgar Link pending
brhc10035487_10k.htm Edgar Link pending
brhc10035487_10k_htm.xml Edgar Link completed
brhc10035487_ex21-1.htm Edgar Link pending
brhc10035487_ex23-1.htm Edgar Link pending
brhc10035487_ex3-1.htm Edgar Link pending
brhc10035487_ex3-1slide1.jpg Edgar Link pending
brhc10035487_ex3-1slide10.jpg Edgar Link pending
brhc10035487_ex3-1slide11.jpg Edgar Link pending
brhc10035487_ex3-1slide12.jpg Edgar Link pending
brhc10035487_ex3-1slide13.jpg Edgar Link pending
brhc10035487_ex3-1slide14.jpg Edgar Link pending
brhc10035487_ex3-1slide15.jpg Edgar Link pending
brhc10035487_ex3-1slide16.jpg Edgar Link pending
brhc10035487_ex3-1slide17.jpg Edgar Link pending
brhc10035487_ex3-1slide18.jpg Edgar Link pending
brhc10035487_ex3-1slide19.jpg Edgar Link pending
brhc10035487_ex3-1slide2.jpg Edgar Link pending
brhc10035487_ex3-1slide20.jpg Edgar Link pending
brhc10035487_ex3-1slide21.jpg Edgar Link pending
brhc10035487_ex3-1slide22.jpg Edgar Link pending
brhc10035487_ex3-1slide23.jpg Edgar Link pending
brhc10035487_ex3-1slide24.jpg Edgar Link pending
brhc10035487_ex3-1slide25.jpg Edgar Link pending
brhc10035487_ex3-1slide26.jpg Edgar Link pending
brhc10035487_ex3-1slide27.jpg Edgar Link pending
brhc10035487_ex3-1slide28.jpg Edgar Link pending
brhc10035487_ex3-1slide29.jpg Edgar Link pending
brhc10035487_ex3-1slide3.jpg Edgar Link pending
brhc10035487_ex3-1slide30.jpg Edgar Link pending
brhc10035487_ex3-1slide31.jpg Edgar Link pending
brhc10035487_ex3-1slide32.jpg Edgar Link pending
brhc10035487_ex3-1slide33.jpg Edgar Link pending
brhc10035487_ex3-1slide34.jpg Edgar Link pending
brhc10035487_ex3-1slide35.jpg Edgar Link pending
brhc10035487_ex3-1slide36.jpg Edgar Link pending
brhc10035487_ex3-1slide37.jpg Edgar Link pending
brhc10035487_ex3-1slide38.jpg Edgar Link pending
brhc10035487_ex3-1slide39.jpg Edgar Link pending
brhc10035487_ex3-1slide4.jpg Edgar Link pending
brhc10035487_ex3-1slide40.jpg Edgar Link pending
brhc10035487_ex3-1slide41.jpg Edgar Link pending
brhc10035487_ex3-1slide42.jpg Edgar Link pending
brhc10035487_ex3-1slide43.jpg Edgar Link pending
brhc10035487_ex3-1slide44.jpg Edgar Link pending
brhc10035487_ex3-1slide45.jpg Edgar Link pending
brhc10035487_ex3-1slide46.jpg Edgar Link pending
brhc10035487_ex3-1slide47.jpg Edgar Link pending
brhc10035487_ex3-1slide48.jpg Edgar Link pending
brhc10035487_ex3-1slide49.jpg Edgar Link pending
brhc10035487_ex3-1slide5.jpg Edgar Link pending
brhc10035487_ex3-1slide50.jpg Edgar Link pending
brhc10035487_ex3-1slide51.jpg Edgar Link pending
brhc10035487_ex3-1slide52.jpg Edgar Link pending
brhc10035487_ex3-1slide53.jpg Edgar Link pending
brhc10035487_ex3-1slide54.jpg Edgar Link pending
brhc10035487_ex3-1slide55.jpg Edgar Link pending
brhc10035487_ex3-1slide56.jpg Edgar Link pending
brhc10035487_ex3-1slide57.jpg Edgar Link pending
brhc10035487_ex3-1slide58.jpg Edgar Link pending
brhc10035487_ex3-1slide59.jpg Edgar Link pending
brhc10035487_ex3-1slide6.jpg Edgar Link pending
brhc10035487_ex3-1slide60.jpg Edgar Link pending
brhc10035487_ex3-1slide61.jpg Edgar Link pending
brhc10035487_ex3-1slide62.jpg Edgar Link pending
brhc10035487_ex3-1slide63.jpg Edgar Link pending
brhc10035487_ex3-1slide7.jpg Edgar Link pending
brhc10035487_ex3-1slide8.jpg Edgar Link pending
brhc10035487_ex3-1slide9.jpg Edgar Link pending
brhc10035487_ex31-1.htm Edgar Link pending
brhc10035487_ex31-2.htm Edgar Link pending
brhc10035487_ex32-1.htm Edgar Link pending
brhc10035487_ex4-19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fwbi-20211231.xsd Edgar Link pending
fwbi-20211231_cal.xml Edgar Link unprocessable
fwbi-20211231_def.xml Edgar Link unprocessable
fwbi-20211231_lab.xml Edgar Link unprocessable
fwbi-20211231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending